BioVaxys to Present New DPX Immune Platform Data at Cancer Vaccine Summit

BioVaxys Technology Corp. has been invited to present their innovative delivery system for personalized peptide and mRNA vaccines at The Personalized Cancer Vaccine Summit in Boston, happening from December 3 to 5, 2024. This summit, previously known as the mRNA Cancer Vaccine Summit, gathers leading industry figures focused on developing individualized cancer vaccine approaches. These include mRNA, DNA, peptide, viral, and dendritic cell technologies, as well as combining these vaccines with immune-checkpoint inhibitors to address various tumor-specific pathways while minimizing off-target effects.

Presenting alongside BioVaxys are other notable organizations such as BioNTec, CureVac, ImVax, The Mayo Clinic, and NEC Biotherapeutics. BioVaxys' Chief Medical Officer, Dr. David Berd, will share new data from recent in vivo studies of DPX. These studies were conducted by Pramrod K. Srivastava, Ph.D., M.D., from UConn Health, and Hakimeh Ebrahimi-Nik, DVM, Ph.D., from The Ohio State University Comprehensive Cancer Center. The results highlight the potential therapeutic roles of DPX and neoepitopes in tumor rejection and showcase DPX's inherent anti-tumor properties.

Kenneth Kovan, President and Chief Operating Officer of BioVaxys, mentioned that detailed findings and potential new therapeutic applications of DPX and neoepitopes will be disclosed at the conference. Preliminary data indicates DPX's significant role in delivering tumor neoepitope vaccines that can induce tumor rejection, along with its own anti-tumor capabilities.

BioVaxys continues to collaborate with Dr. Nik and her research team on further studies involving DPX's ability to deliver tumor neoepitope vaccines and its anti-tumor properties.

BioVaxys Technology Corp., registered in British Columbia, Canada, is a clinical-stage biopharmaceutical firm committed to enhancing patient lives through novel immunotherapies. These are based on its DPX™ immune-educating technology platform and its HapTenix© "neoantigen" tumor cell construct platform. These platforms target a range of conditions, including cancers, infectious diseases, antigen desensitization, and other immunological disorders. The DPX™ platform works by instructing the immune system to generate a specific, robust, and enduring immune response.

Among the company's clinical-stage pipeline products is maveropepimut-S (MVP-S), which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer. MVP-S is based on the DPX™ platform and delivers antigenic peptides from survivin, a cancer antigen commonly overexpressed in advanced cancers. It also includes an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has shown good tolerance and significant clinical benefits in multiple cancer indications, along with the activation of a targeted and sustained survivin-specific anti-tumor immune response.

Additionally, BioVaxys is developing DPX™+SurMAGE, a dual-targeted immunotherapy that combines antigenic peptides for both survivin and MAGE-A9 cancer proteins to elicit immune responses against these two distinct antigens simultaneously. Other products in development include DPX™-RSV for Respiratory Syncytial Virus and BVX-0918, a personalized immunotherapeutic vaccine for refractory late-stage ovarian cancer using the HapTenix© "neoantigen" tumor cell construct platform.

BioVaxys' common shares are listed on the Canadian Securities Exchange under the symbol "BIOV" and trade on the Frankfurt Stock Exchange and OTC Markets in the US.